These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33201204)

  • 41. Germline Genetic Features of Young Individuals With Colorectal Cancer.
    Stoffel EM; Koeppe E; Everett J; Ulintz P; Kiel M; Osborne J; Williams L; Hanson K; Gruber SB; Rozek LS
    Gastroenterology; 2018 Mar; 154(4):897-905.e1. PubMed ID: 29146522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rare germline genetic variants and risk of aggressive prostate cancer.
    Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC
    Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
    J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer.
    Chávarri-Guerra Y; Bourlon MT; Rodríguez-Olivares JL; Orozco L; Bazua D; Rodríguez-Faure A; Alcalde-Castro MJ; Castro E; Castillo D; Herzog J; Weitzel J
    Clin Genitourin Cancer; 2023 Oct; 21(5):569-573. PubMed ID: 37380563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Limited-Variant Screening vs Comprehensive Genetic Testing for Familial Hypercholesterolemia Diagnosis.
    Sturm AC; Truty R; Callis TE; Aguilar S; Esplin ED; Garcia S; Haverfield EV; Morales A; Nussbaum RL; Rojahn S; Vatta M; Rader DJ
    JAMA Cardiol; 2021 Aug; 6(8):902-909. PubMed ID: 34037665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data.
    Liu J; Zhao H; Zheng Y; Dong L; Zhao S; Huang Y; Huang S; Qian T; Zou J; Liu S; Li J; Yan Z; Li Y; Zhang S; Huang X; Wang W; Li Y; Wang J; Ming Y; Li X; Xing Z; Qin L; Zhao Z; Jia Z; Li J; Liu G; Zhang M; Feng K; Wu J; Zhang J; Yang Y; Wu Z; Liu Z; Ying J; Wang X; Su J; Wang X; Wu N
    Genome Med; 2022 Feb; 14(1):21. PubMed ID: 35209950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
    Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
    BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Multigene Testing for Prostate Cancer.
    Berro T; Barrett E; AlDubayan SH
    Urol Clin North Am; 2021 Aug; 48(3):297-309. PubMed ID: 34210486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
    Ledet EM; Burgess EF; Sokolova AO; Jaeger EB; Hatton W; Moses M; Miller P; Cotogno P; Layton J; Barata P; Lewis BE; Nakazawa M; Zhu J; Dellinger B; Elrefai S; Nafissi NN; Egan JB; Shore N; McKay RR; Bryce AH; Cheng HH; Antonarakis ES; Sartor O
    Prostate; 2021 May; 81(7):433-439. PubMed ID: 33792945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases.
    Zeng C; Bastarache LA; Tao R; Venner E; Hebbring S; Andujar JD; Bland ST; Crosslin DR; Pratap S; Cooley A; Pacheco JA; Christensen KD; Perez E; Zawatsky CLB; Witkowski L; Zouk H; Weng C; Leppig KA; Sleiman PMA; Hakonarson H; Williams MS; Luo Y; Jarvik GP; Green RC; Chung WK; Gharavi AG; Lennon NJ; Rehm HL; Gibbs RA; Peterson JF; Roden DM; Wiesner GL; Denny JC
    JAMA Oncol; 2022 Jun; 8(6):835-844. PubMed ID: 35446370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
    Yap TA; Ashok A; Stoll J; Mauer E; Nepomuceno VM; Blackwell KL; Garber JE; Meric-Bernstam F
    JAMA Netw Open; 2022 May; 5(5):e2213070. PubMed ID: 35594047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association Between Genotype and Phenotype in Consecutive Unrelated Individuals With Retinoblastoma.
    Salviat F; Gauthier-Villars M; Carton M; Cassoux N; Lumbroso-Le Rouic L; Dehainault C; Levy C; Golmard L; Aerts I; Doz F; Bonnet-Serrano F; Hayek S; Savignoni A; Stoppa-Lyonnet D; Houdayer C
    JAMA Ophthalmol; 2020 Aug; 138(8):843-850. PubMed ID: 32556071
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.
    Momozawa Y; Sasai R; Usui Y; Shiraishi K; Iwasaki Y; Taniyama Y; Parsons MT; Mizukami K; Sekine Y; Hirata M; Kamatani Y; Endo M; Inai C; Takata S; Ito H; Kohno T; Matsuda K; Nakamura S; Sugano K; Yoshida T; Nakagawa H; Matsuo K; Murakami Y; Spurdle AB; Kubo M
    JAMA Oncol; 2022 Jun; 8(6):871-878. PubMed ID: 35420638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
    Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
    Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessing actionability and incidental findings of germline variants in two precision oncology trials.
    Ibrahim MB; Adnani Y; Clément GJ; Lacroix L; Loriot Y; Besse B; Massard C; Rouleau E
    Eur J Cancer; 2024 Oct; 210():114256. PubMed ID: 39154486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia.
    Gupta S; Erickson LA; Lohse CM; Shen W; Pitel BA; Knight SM; Halling KC; Herrera-Hernandez L; Boorjian SA; Thompson RH; Leibovich BC; Jimenez RE; Cheville JC
    JAMA Netw Open; 2021 Nov; 4(11):e2132615. PubMed ID: 34767027
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature.
    Sylvester DE; Chen Y; Jamieson RV; Dalla-Pozza L; Byrne JA
    J Med Genet; 2018 Dec; 55(12):785-793. PubMed ID: 30287599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.